1-3 of 3
Paul White, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Efficacy of the FLT3 Inhibitor Lestaurtinib in AML Depends on Adequate Plasma Inhibitory Activity (PIA), and Is Unaffected by Rising FLT Ligand Levels: An Update of the NCRI AML15 & 17 Trials

Steven Knapper, DM MRCP FRCPath, Paul White, PhD, Mark J. Levis, MD, PhD, Robert K Hills, MA, MSc, DPhil, Nigel H. Russell, MD, Alan Burnett, MD, ChB, FRCP, FRCPath, FMedSci
Journal: Blood
Blood (2011) 118 (21): 421.
https://doi.org/10.1182/blood.V118.21.421.421
Published: 2011
Journal Articles

Analysis of the Interaction of Induction Regimens with P-Glycoprotein Expression In Patients with Acute Myeloid Leukaemia: Results From the MRC AML15 Trial

Monica Pallis, PhD, Paul White, PhD, Robert Hills, MA, MSc, DPhil, Martin Grundy, BSc, Nigel H. Russell, MD, Alan Burnett
Journal: Blood
Blood (2010) 116 (21): 2724.
https://doi.org/10.1182/blood.V116.21.2724.2724
Published: 2010
Journal Articles

Competing Influences of Genetic and Leukaemia-Specific Factors on P-Glycoprotein Expression in Blasts from 817 Patients Entered into the NCRN AML14 and 15 Trials.

Claire H. Seedhouse, PhD, Martin Grundy, BSc, Paul White, PhD, Yun Li, MSc, Janet Fisher, BSc, Darya Yakunina, MD, Anthony Moorman, PhD, Nigel Russell, MD, Alan Burnett, MD, Monica Pallis, PhD
Journal: Blood
Blood (2006) 108 (11): 835.
https://doi.org/10.1182/blood.V108.11.835.835
Published: 2006